Ulcerative Colitis | Unmet Need | US/EU | 2022

Tumor necrosis factor (TNF)-alpha inhibitors (e.g., Janssen’s Remicade, AbbVie’s Humira, biosimilars of both drugs where available) are the mainstay of biological treatment for moderate to severe ulcerative colitis (UC). However, these agents carry safety risks and have efficacy limitations. Takeda’s Entyvio (a cell adhesion molecule [CAM] inhibitor), Pfizer’s Xeljanz / Xeljanz XR (an oral Janus-activated kinase [JAK] inhibitor), Janssen’s Stelara (an interleukin [IL]-12/23 inhibitor), and BMS’s Zeposia (an oral S1P-R modulator) have expanded the treatment options for moderate to severe UC, but despite the number of available agents, significant unmet need remains, especially for patients refractory to these therapies. Although several agents in late-phase development (including additional JAK inhibitors and S1P-R modulators and molecules with novel mechanisms of action [e.g., IL-23 inhibitors]) are poised to enter the moderate to severe UC market over the next several years, their ability to fulfill these unmet needs remains to be seen.

QUESTIONS ANSWERED

• What are the treatment drivers and goals in moderate to severe UC?
• How do TNF-α inhibitors (branded and biosimilars) and other targeted therapies (i.e., Entyvio, Stelara, Zeposia, and Xeljanz / Xeljanz XR) perform on treatment drivers and goals?
• In addition to efficacy, what other drug attributes influence physician prescribing behavior the most, and which attributes have a limited impact?
• What are the prevailing areas of unmet need and hidden opportunity in the treatment of moderate to severe UC?
• What trade-offs in terms of clinical attributes and price are acceptable to U.S. and European gastroenterologists for a hypothetical new UC drug?

PRODUCT DESCRIPTION

Provides quantitative insight into U.S. and European physician perceptions of key treatment drivers and goals and the current level of unmet need for a specific disease. Commercial opportunities are analyzed, and the extent to which emerging therapies may capitalize on these opportunities is evaluated.

Markets covered: United States, United Kingdom, France, Germany

Primary research: Survey of 61 U.S. and 31 European gastroenterologists fielded in February 2022

Key companies: AbbVie, Janssen, Takeda, Pfizer, Eli Lilly, Bristol Myers Squibb, Celltrion Healthcare

Key drugs: Humira, adalimumab biosimilar, Remicade, infliximab biosimilar (IV), Remsima SC, Entyvio, Xeljanz / Xeljanz XR, Stelara, Zeposia, Rinvoq, Jyseleca